Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) — Market Cap & Net Worth
Market Cap & Net Worth: Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a market capitalization of $2.14 Billion ($2.14 Billion) as of October 11, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5880 globally and #1895 in its home market, demonstrating a 4.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aurinia Pharmaceuticals Inc's stock price $16.65 by its total outstanding shares 133051168 (133.05 Million).
Aurinia Pharmaceuticals Inc Market Cap History: 2015 to 2026
Aurinia Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $328.64 Million to $2.22 Billion (16.54% CAGR). Check latest Aurinia Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Index Memberships
Aurinia Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.08% | #156 of 976 |
|
NASDAQ Composite
IXIC
|
$42.19 Trillion | 0.01% | #661 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.12% | #97 of 263 |
Weight: Aurinia Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aurinia Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aurinia Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Aurinia Pharmaceuticals Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
7.50x
Aurinia Pharmaceuticals Inc's market cap is 7.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.39x
Aurinia Pharmaceuticals Inc's market cap is 7.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $279.41 Million | $173.00K | -$23.30 Million | 1615.07x | N/A |
| 2017 | $602.72 Million | $420.00K | -$70.79 Million | 1435.05x | N/A |
| 2018 | $907.41 Million | $463.00K | -$64.12 Million | 1959.85x | N/A |
| 2019 | $2.70 Billion | $318.00K | -$88.39 Million | 8476.78x | N/A |
| 2020 | $1.84 Billion | $50.12 Million | -$102.68 Million | 36.72x | N/A |
| 2021 | $3.04 Billion | $45.60 Million | -$180.97 Million | 66.72x | N/A |
| 2022 | $574.78 Million | $134.03 Million | -$108.18 Million | 4.29x | N/A |
| 2023 | $1.20 Billion | $175.51 Million | -$78.02 Million | 6.82x | N/A |
| 2024 | $1.20 Billion | $235.13 Million | $5.75 Million | 5.10x | 208.30x |
| 2025 | $2.12 Billion | $283.06 Million | $287.20 Million | 7.50x | 7.39x |
Competitor Companies of AUPH by Market Capitalization
Companies near Aurinia Pharmaceuticals Inc in the global market cap rankings as of October 11, 2026. See AUPH net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to Aurinia Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Aurinia Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Aurinia Pharmaceuticals Inc's market cap moved from $328.64 Million to $ 2.22 Billion, with a yearly change of 16.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.22 Billion | +4.39% |
| 2025 | $2.12 Billion | +77.12% |
| 2024 | $1.20 Billion | +0.17% |
| 2023 | $1.20 Billion | +108.10% |
| 2022 | $574.78 Million | -81.11% |
| 2021 | $3.04 Billion | +65.37% |
| 2020 | $1.84 Billion | -31.74% |
| 2019 | $2.70 Billion | +197.07% |
| 2018 | $907.41 Million | +50.55% |
| 2017 | $602.72 Million | +115.71% |
| 2016 | $279.41 Million | -14.98% |
| 2015 | $328.64 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Aurinia Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.14 Billion USD |
| MoneyControl | $2.14 Billion USD |
| MarketWatch | $2.14 Billion USD |
| marketcap.company | $2.14 Billion USD |
| Reuters | $2.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more